Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESM responsiveness to linaclotide treatment in IBS-C
NL-OMON50476Active, not recruiting
- Sponsor
- Maastricht University
- Start
- Feb 2018
- Modality
- Peptides
- Countries
- 1
01
Overview
Open-label trial of linaclotide in irritable bowel syndrome (IBS), sponsored by Maastricht University. Primary endpoints: Overall responder proportion at 4 weeks by ESM-PROM, Overall responder proportion at 12 weeks by ESM-PROM and 2 more. Started Feb 2018; status: active, not recruiting.
02
Drugs
linaclotide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NL-OMON50476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50476.